Background
==========

Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) was initially recognized by the mouse monoclonal antibody 22-1-1, which was raised by immunization of mice with the human uterine cervical adenocarcinoma cell line SiSo \[[@b1-medscimonit-18-4-br123]\]. It is a 40-kd type II membrane protein that forms homo-oligomers through its C-terminal coiled-coil structures, whereas it also exists in soluble form, probably by alternative splicing \[[@b2-medscimonit-18-4-br123]\]. RCAS1 has currently been considered as a novel tumor-associated antigen that induces cell-cycle arrest and/or apoptosis in RCAS1 receptor-bearing human cells \[[@b3-medscimonit-18-4-br123]\]. Substantial evidence also supports that RCAS1 can function as a ligand for a putative receptor present on various human cell lines such as erythroid leukemia, K562 cells, and normal peripheral lymphocytes such as T, B and NK cells, inhibiting cell growth and inducing apoptosis \[[@b4-medscimonit-18-4-br123]\]. Notably, several studies documented that tumor cells may develop the ability to evade immune surveillance by several mechanisms, including RCAS1 up-regulation, and that RCAS1 positive tumor cells may induce apoptosis to their surrounding tumor infiltrating lymphocytes (TILs) \[[@b5-medscimonit-18-4-br123],[@b6-medscimonit-18-4-br123]\]. Thus, it is speculated that RCAS1 can exert oncogenic properties, leading to immune cell depletion in several types of neoplasia \[[@b7-medscimonit-18-4-br123]\].

Benign and malignant thyroid lesions constitute the most common neoplasia of endocrine glands, with growing rates during the last 2 decades \[[@b8-medscimonit-18-4-br123],[@b9-medscimonit-18-4-br123]\]. The rapidly increasing incidence of thyroid cancer has mainly been attributed to the improvement in detection of small papillary tumors \[[@b10-medscimonit-18-4-br123]--[@b13-medscimonit-18-4-br123]\]. Most thyroid tumors can be readily diagnosed using histopathological criteria, allowing the pathologist to distinguish malignant from benign lesions and guarantying accurate classification for the majority of thyroid carcinoma variants \[[@b14-medscimonit-18-4-br123]\]. However, in many cases the distinction between benign and malignant is quite subtle and the decision favoring one or another has clinical consequences and implies different treatment modalities \[[@b14-medscimonit-18-4-br123]\]. Currently, there has been considerable progress in identifying biomarkers in thyroid tumors that improve the accuracy of fine-needle aspiration biopsy and contribute to the accurate estimation of tumor aggressiveness or behavior \[[@b15-medscimonit-18-4-br123]--[@b17-medscimonit-18-4-br123]\].

In the last few years, RCAS1 protein expression has been described in a variety of human malignancies, being correlated with demographic and clinicopathological characteristics of therapeutic and prognostic significance \[[@b7-medscimonit-18-4-br123]\]. Notably, RCAS1 has been reported to be expressed in several head and neck neoplasms, including oral, esophageal and thyroid carcinoma \[[@b18-medscimonit-18-4-br123]--[@b25-medscimonit-18-4-br123]\]. RCAS1 overexpression was significantly associated with the dedifferentiation of thyroid carcinoma, being more frequently observed in anaplastic compared to papillary and follicular variants \[[@b25-medscimonit-18-4-br123]\]. However, there are no available studies evaluating whether RCAS1 protein detection by immunohistochemistry can distinguish benign from malignant thyroid lesions and whether it correlates with tumor characteristics. In view of above considerations, the present study aimed to assess the immunohistochemical RCAS1 expression in a large series of benign and malignant thyroid lesions and to evaluate its diagnostic utility. The association of RCAS1 immunostaining with tumor stage parameters, such as tumor size, lymph node metastases, and capsular, lymphatic and vascular invasion was also examined.

Material and Methods
====================

Patients
--------

One hundred twenty-one formalin-fixed, paraffin-embedded thyroid tissues from an equal number of patients who had undergone thyroid surgery for benign or malignant disease were included in this study. Informed consent was obtained from all patients. None of the patients received any kind of anti-cancer treatment prior to surgery. Each case was classified according to the WHO histological classification of thyroid tumors \[[@b26-medscimonit-18-4-br123]\]. The clinical material consisted of 68 benign (59 hyperplastic nodules and 9 Hashimoto thyroiditis) and 53 malignant (41 papillary, 5 medullary, 5 follicular and 2 anaplastic thyroid carcinomas) cases. The characteristics of the population under study categorized into benign and malignant thyroid lesions are summarized in [Table 1](#t1-medscimonit-18-4-br123){ref-type="table"}.

Immunohistochemistry
--------------------

RCAS1 immunostaining was performed on formalin-fixed, paraffin-embedded thyroid tissue sections using a mouse monoclonal anti-RCAS1 antibody (MBL International Co, Nagoya, Japan) as previously described \[[@b27-medscimonit-18-4-br123]\]. Appropriate negative controls were performed by omitting the primary antibody and/or substituting it with an irrelevant anti-serum. Pancreatic cancer tissue sections with known increased RCAS1 immunoreactivity were used as positive control \[[@b27-medscimonit-18-4-br123]\]. Follicular cells' proliferative capacity was assessed immunohistochemically using a mouse anti-human Ki-67 antigen; IgG~1k~ antibody (clone MIB-1, Dakopatts, Glostrup, Denmark), as previously described (28, 29).

Evaluation of immunohistochemistry
----------------------------------

Stained sections were independently assessed by S.T. and P.A., who were blinded to the clinical data, with complete observers' agreement. Specimens were considered "positive" for RCAS1 when more than 5% of follicular cells within the section were positively stained (28, 29). The extent of RCAS1 expression was calculated by the percentage of the RCAS1-positive follicular cells in the total number of follicular cells within each specimen. The specimens were characterized to present overexpression for RCAS1 when the percentage of the positively stained follicular cells exceeded the mean percentage value \[[@b27-medscimonit-18-4-br123]\]. In RCAS1-positive cases, the intensity of immunostaining was also estimated and graded in a 3 step scale as weak (+), moderate (++) and strong (+++) \[[@b27-medscimonit-18-4-br123]\]. Ki-67 labeling index was classified into 2 categories, below and over mean value, as previously described ([Table 2](#t2-medscimonit-18-4-br123){ref-type="table"}) \[[@b28-medscimonit-18-4-br123],[@b29-medscimonit-18-4-br123]\].

Statistical analysis
--------------------

Chi-square tests were used to assess the difference of RCAS1 positivity, overexpression and staining intensity between malignant and benign thyroid lesions, as well as between papillary carcinoma and hyperplastic nodules, which comprise the most numerous histopathological entities of malignant and benign lesions, respectively. Chi-square tests were also performed to assess the association of RCAS1 positivity, overexpression and staining intensity with clinicopathological characteristics in the subgroup of malignant thyroid cases. Mann-Whitney U test and Kolmogorov-Smirnov test were further applied to evaluate the difference in the percentage of RCAS1-positive stained follicular cells between malignant and benign thyroid lesions, as well as between papillary carcinoma and hyperplastic nodules. A 2-tailed p\<0.05 was considered statistically significant. Statistical analyses were performed using the software package SPSS for Windows (version 11.0; SPSS Inc., Chicago, IL, USA).

Results
=======

RCAS1 positivity was noted in 68 out of 121 cases (56%) with thyroid lesions. The pattern of RCAS1 distribution was both cytoplasmic and membranous in all positive cases. Normal thyroid tissue was found negative for RCAS1. Representative RCAS1 immunostainings in cases with papillary and follicular carcinoma, as well as hyperplastic nodule and Hashimoto thyroiditis, are depicted in [Figure 1](#f1-medscimonit-18-4-br123){ref-type="fig"}. Forty-two out of 121 cases (35%) showed overexpression for RCAS1, while 50 cases (41%) presented moderate/strong RCAS1 staining intensity ([Tables 3](#t3-medscimonit-18-4-br123){ref-type="table"}, [4](#t4-medscimonit-18-4-br123){ref-type="table"}).

RCAS1 positivity, overexpression and staining intensity provided statistically significant discriminations between cases with malignant and benign thyroid lesions (p=0.0006, p=0.0001 and p=0.0001, respectively), as well as between cases with hyperplastic nodule and papillary carcinoma (p=0.0229, p=0.0001 and p=0.0001, respectively). RCAS1 positivity, overexpression and staining intensity also provided a distinct discrimination between cases with Hashimoto thyroiditis and those with hyperplastic nodules (p=0.0221, p=0.0001 and p=0.0019, respectively). RCAS1 positivity, overexpression and staining intensity was positively associated with follicular cells proliferative capacity, reflected by Ki-67 labelling index (p=0.0007, p=0.0039 and p=0.0077, respectively). An increased incidence of RCAS1 positivity and moderate/strong RCAS1 staining intensity in female compared to male patients was noted, without reaching statistical significance (p=0.1071 and p=0.0924, respectively).

Mann-Whitney U tests and Kolmogorov-Smirnov tests were further performed to assess whether the percentage of RCAS1-positive stained follicular cells could provide discrimination among the different histopathological entities of thyroid malignancy. The percentage of RCAS1-positive stained follicular cells was significantly increased in cases with malignant compared to those with benign thyroid lesions ([Figure 2A](#f2-medscimonit-18-4-br123){ref-type="fig"}, mean percent RCAS1 positive staining: 35.51±29.91% *vs.* 11.43±21.87%, p=0.0001). Papillary carcinoma cases showed significantly increased percentage of RCAS1-positive stained follicular cells compared to those with hyperplastic nodules ([Figure 2B](#f2-medscimonit-18-4-br123){ref-type="fig"}, mean percent RCAS1-positive staining: 35.73±32.28% *vs.* 6.64±15.08%, p=0.0003). The percentage of RCAS1-positive stained follicular cells was also significantly increased in cases with Hashimoto thyroiditis compared to those with hyperplastic nodules (mean percent RCAS1-positive staining: 42.7±832.89% *vs.* 6.64±15.08%, p=0.0015).

We also assessed whether RCAS1 positivity, overexpression and staining intensity bears a pronounced diagnostic effect on patients with malignant thyroid lesions. We stratified by pT stage (small *vs.* large tumor size, pT1 *vs.* pT2-4), lymph nodal status (absence *vs.* presence of lymph node metastases, pN0 *vs.* pN1), and capsular, lymphatic and vascular invasion (absence *vs.* presence of invasion). In cross-tables, the incidence of RCAS1-positivity was borderline increased in patients with tumors exhibiting large size (pT, p=0.0964) and capsular invasion (p=0.0779). RCAS1 overexpression was significantly more frequently observed in patients having tumors with large size (pT, p=0.0246), presence of lymph node metastases (p=0.0351) and capsular invasion (p=0.0397), while a correlation trend with vascular invasion (p=0.0549) was also noted. RCAS1 staining intensity was not associated with any demographic and clinicopathological parameters in the subgroup of patients with malignant thyroid lesions.

Discussion
==========

It is well-established that RCAS1 is overexpressed in various tumors and seems to affect many aspects of cancer biology such as differentiation, proliferation, invasion and angiogenesis \[[@b6-medscimonit-18-4-br123],[@b7-medscimonit-18-4-br123]\]. Elevated RCAS1 expression has been associated with tumor malignancy in several tissue types, being considered to exert a crucial role in tumor progression by enabling cancer cells to evade immune surveillance \[[@b6-medscimonit-18-4-br123],[@b7-medscimonit-18-4-br123]\]. However, assessment of the clinical significance of RCAS1 expression in thyroid neoplasia remains scarce \[[@b15-medscimonit-18-4-br123]\]. In this context, the present study aimed to assess the diagnostic utility of RCAS1 expression in thyroid neoplasia and its association with clinicopathological parameters crucial for patients' management and prognosis.

We showed that RCAS1 immunoreactivity (positivity, overexpression and staining intensity) was significantly increased in cases with malignant compared to those with benign thyroid lesions. Such a distinct discrimination was also obtained between cases with papillary carcinoma and those with hyperplastic nodule, which comprise the most common histopathological entities of malignant and benign thyroid lesions. Moreover, in the subgroup of malignant thyroid lesions, RCAS1 overexpression was significantly associated with large tumor size, the presence of lymph node metastases and capsular invasion. These findings suggest that RCAS1 protein may participate in thyroid neoplastic transformation and could be considered as a potential marker to improve diagnostic scrutiny. In line with the present study, Ito et al showed that normal epithelium and follicular adenoma did not express or only faintly expressed RCAS1 \[[@b25-medscimonit-18-4-br123]\]. Remarkably, in the subgroup of thyroid carcinomas, the same study clearly indicated that RCAS1 overexpression was significantly associated with tumor dedifferentiation, being more frequently observed in anaplastic compared to papillary and follicular carcinomas \[[@b25-medscimonit-18-4-br123]\]. We further showed that cases with Hashimoto thyroiditis presented significantly increased RCAS1 immunoreactivity compared to those with hyperplastic nodules, with a mean percentage value of RCAS1-positive stained follicular cells slightly higher that that observed in papillary carcinomas. In this aspect, it should be noted that although Hashimoto thyroiditis is considered as a benign condition, it almost always harbors a genetic rearrangement that is strongly associated with and is highly specific for papillary thyroid carcinoma \[[@b30-medscimonit-18-4-br123]\].

RCAS1 expression has been well-described in several types of head and neck neoplasia. More to the point, in oral squamous cell carcinoma (SCC), enhanced RCAS1 expression was significantly associated with large tumor size, presence of lymph node metastases, advanced disease stage and poor prognosis \[[@b18-medscimonit-18-4-br123],[@b20-medscimonit-18-4-br123]\]. Notably, enhanced RCAS1 expression was significantly associated with the presence of apoptotic TILs in this type of malignancy \[[@b18-medscimonit-18-4-br123],[@b19-medscimonit-18-4-br123]\]. Moreover, in esophageal SCC, increased RCAS1 expression was significantly associated with advanced disease stage, presence of lymph node metastasis and poor patient survival \[[@b21-medscimonit-18-4-br123]--[@b24-medscimonit-18-4-br123]\]. Preliminary studies by our group also showed that RCAS1 expression was significantly associated with muscular invasion, depth of invasion, mitotic index and stromal inflammatory reaction in mobile tongue SCC (Theocharis et al, unpublished data). Data from different studies points towards combined functional properties of RCAS1. The expression of RCAS1 putative receptor was found to be enhanced in lymphocytes activated by IL-2 \[[@b3-medscimonit-18-4-br123]--[@b6-medscimonit-18-4-br123]\]. Secreted RCAS1 also inhibited the growth of such activated cells *in vitro* by inducing their apoptotic cell death \[[@b3-medscimonit-18-4-br123]--[@b6-medscimonit-18-4-br123]\]. In this aspect, it was suggested that tumor cells may evade immune surveillance by expressing RCAS1 \[[@b31-medscimonit-18-4-br123]--[@b33-medscimonit-18-4-br123]\]. Moreover, RCAS1 was shown to facilitate tumor cell invasion of connective tissue in uterine cervical cancer by induction of stromal tissue remodeling, as well as through evasion of antitumor immune surveillance by an apoptotic counter-attack mechanism against lymphocytes \[[@b6-medscimonit-18-4-br123],[@b32-medscimonit-18-4-br123],[@b33-medscimonit-18-4-br123]\].

Conclusions
===========

RCAS1 protein expression detected by immunohistochemistry proved to be a useful diagnostic marker for discriminating malignant from benign thyroid cases and papillary carcinoma from hyperplastic nodules. The association of RCAS1 protein expression with tumor stage provided evidence for its possible implication in the development and progression of thyroid carcinoma. Further studies applying Western blot analysis and fluorescent techniques, as well as quantitative microscopy and correlation with additional markers for cell differentiation and behavior, should be performed to elucidate the underlining pathogenetic mechanisms. As RCAS1 is easily detectable in biofluids (34), further research effort should focus on the determination of RCAS1 levels in serum or plasma before and after treatment, with the aim of recognizing recurrence.

**Source of support:** Departmental sources

![Representative immunostainings of RCAS1 protein expression in malignant thyroid cases with (**A**). Papillary carcinoma and (**B**). Follicular carcinoma and in benign thyroid cases with (**C**). Hyperplastic nodules and (**D**). Hashimoto thyroiditis (Original magnification ×400, Streptavidin-biotin-peroxidase, DAB chromogen, Harris hematoxylin counterstain).](medscimonit-18-4-BR123-g001){#f1-medscimonit-18-4-br123}
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###### 

Study population characteristics.

  Clinicopathological parameters   Benign                                                       Malignant
  -------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------
  **N=121**                        68 (56%)                                                     53 (44%)
                                                                                                
  **Age** (mean ±SD; ys)           48.95±14.21                                                  50.09±15.37
  49.38±15.11                                                                                   
                                                                                                
  **Gender**                                                                                    
                                                                                                
  Male                             15 (12%)                                                     11 (9%)
                                                                                                
  Female                           53 (44%)                                                     42 (35%)
                                                                                                
  **Histopathology**               Hyperplastic nodule                                          Papillary
  59 (49%)                         41 (34%)                                                     
                                                                                                
  Hashimoto thyroiditis            Medullary                                                    
  9 (7%)                           5 (4%)                                                       
                                                                                                
                                   Follicular                                                   
                                   5 (4%)                                                       
                                                                                                
                                   Anaplastic                                                   
                                   2 (2%)                                                       
                                                                                                
  **Tumor size (T)**               N/A[\*](#tfn1-medscimonit-18-4-br123){ref-type="table-fn"}   
                                                                                                
  T1                                                                                            36 (68%)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  T2                                                                                            13 (24%)
                                                                                                
  T3                                                                                            2 (4%)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  T4                                                                                            2 (4%)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  **Lymph node metastases (N)**    N/A                                                          
                                                                                                
  N0                                                                                            47 (89%)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  N1                                                                                            6 (11%)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  **Distant metastases (M)**       N/A                                                          
                                                                                                
  M0                                                                                            53 (100%)
                                                                                                
  **Capsular invasion**            N/A                                                          
                                                                                                
  No                                                                                            40 (75%)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  Yes                                                                                           13 (25%)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  **Lymphatic invasion**           N/A                                                          
                                                                                                
  No                                                                                            44 (83%)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  Yes                                                                                           9 (17%)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  **Vessel invasion**              N/A                                                          
                                                                                                
  No                                                                                            50 (94%)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  Yes                                                                                           3 (6)[\*\*](#tfn2-medscimonit-18-4-br123){ref-type="table-fn"}
                                                                                                
  **Ki-67 protein statement**                                                                   p-value=0.0019
                                                                                                
  \< mean value                    56 (46%)                                                     30 (25%)
                                                                                                
  ≥ mean value                     12 (10%)                                                     23 (19%)

N/A -- not applicable;

percentages in parentheses correspond to the number of malignant thyroid cases.

###### 

Associations of RCAS1 positivity with patients' clinicopathological characteristics.

  Clinicopathological characteristics   RCAS1 positivity   p-value       
  ------------------------------------- ------------------ ------------- ------------
  **All cases, N=121**                  53 (44)            68 (56)       
  **Age** (mean ±SD; ys)                49.87±12.76        51.09±18.12   0.5097
  **Gender**                                                             
  Female                                38 (31)            57 (47)       0.1071
  Male                                  15 (12)            11 (9)        
  **Histopathology**                                                     
  Benign                                39 (32)            29 (24)       **0.0006**
  Malignant                             14 (12)            39 (32)       
  **Ki-67 protein statement**                                            
  \< mean value                         46 (38)            40 (33)       **0.0007**
  ≥ mean value                          7 (6)              28 (23)       
  **Malignant cases, N=53**             14 (26)            39 (74)       
  **Tumor size (T)**                                                     **0.0964**
  T1                                    12 (23)            24 (45)       
  T2-4                                  2 (4)              15 (28)       
  **Lymph node metastases (N)**                                          0.1191
  N0                                    14 (26)            33 (62)       
  N1                                    0 (0)              6 (11)        
  **Capsular invasion**                                                  **0.0779**
  No                                    13 (25)            27 (51)       
  Yes                                   1 (2)              12 (23)       
  **Lymphatic invasion**                                                 0.2530
  No                                    13 (25)            31 (58)       
  Yes                                   1 (2)              8 (15)        
  **Vascular invasion**                                                  
  No                                    14 (26)            36 (68)       0.2853
  Yes                                   0 (0)              3 (6)         

###### 

Associations of RCAS1 overexpression with patients' clinicopathological characteristics.

  Clinicopathological characteristics   RCAS1 overexpression   p-value       
  ------------------------------------- ---------------------- ------------- ------------
  **All cases, N=121**                  79 (65)                42 (35)       
  **Age** (mean ±SD; ys)                49.31±12.11            51.82±18.33   0.5908
  **Gender**                                                                 
  Female                                61 (50)                34 (28)       0.6337
  Male                                  18 (15)                8 (7)         
  **Histopathology**                                                         
  Benign                                58 (48)                10 (8)        **0.0001**
  Malignant                             21 (17)                32 (26)       
  **Ki-67 protein statement**                                                
  \< mean value                         63 (52)                23 (19)       **0.0039**
  ≥ mean value                          16 (13)                19 (16)       
  **Malignant cases, N=53**             21 (40)                32 (60)       
  **Tumor size (T)**                                                         **0.0246**
  T1                                    18 (34)                18 (34)       
  T2-4                                  3 (6)                  14 (26)       
  **Lymph node metastases (N)**                                              **0.0351**
  N0                                    21 (40)                26 (49)       
  N1                                    0 (0)                  6 (11)        
  **Capsular invasion**                                                      **0.0397**
  No                                    19 (36)                21 (40)       
  Yes                                   2 (4)                  11 (21)       
  **Lymphatic invasion**                                                     0.0549
  No                                    20 (38)                24 (45)       
  Yes                                   1 (2)                  8 (15)        
  **Vascular invasion**                                                      
  No                                    21 (40)                29 (55)       0.1485
  Yes                                   0 (0)                  3 (6)         

###### 

Associations of RCAS1 staining intensity with patients' clinicopathological characteristics.

  Clinicopathological characteristics   RCAS1 staining intensity   p-value       
  ------------------------------------- -------------------------- ------------- ------------
  All cases, N=121                      71 (59)                    50 (41)       
  **Age** (mean ±SD; ys)                49.02±12.45                51.44±18.56   0.7374
  **Gender**                                                                     
  Female                                52 (43)                    43 (36)       0.0924
  Male                                  19 (16)                    7 (6)         
  **Histopathology**                                                             
  Benign                                51 (42)                    17 (14)       **0.0001**
  Malignant                             20 (17)                    33 (27)       
  **Ki-67 protein statement**                                                    
  \< mean value                         57 (47)                    29 (24)       **0.0077**
  ≥ mean value                          14 (12)                    21 (17)       
  **Malignant cases, N=53**             20 (38)                    33 (62)       
  **Tumor size (T)**                                                             0.8010
  T1                                    14 (26)                    22 (42)       
  T2-4                                  6 (11)                     11 (21)       
  **Lymph node metastases (N)**                                                  0.8132
  N0                                    18 (34)                    29 (55)       
  N1                                    2 (4)                      4 (8)         
  **Capsular invasion**                                                          0.5508
  No                                    16 (30)                    24 (45)       
  Yes                                   4 (8)                      9 (17)        
  **Lymphatic invasion**                                                         0.7649
  No                                    17 (32)                    27 (51)       
  Yes                                   3 (6)                      6 (11)        
  **Vascular invasion**                                                          
  No                                    20 (38)                    30 (57)       0.1650
  Yes                                   0 (0)                      3 (6)         
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